Puma Biotechnology
Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Inc
Alan H. Auerbach - Founder, Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile
Puma Biotech's Breast Cancer Drug Results Mint New Billionaire Overnight
Puma Biotechnology
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Articles about Puma Biotechnology | page 6
Puma Biotechnology
Puma Biotechnology
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology, Inc. | LinkedIn
